The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Analyst Says Pharma Co. 'Meaningfully Undervalued'

Research Report
  ()
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.

Biopharma Co. Ceases Program to Optimize Resources

Research Report
  ()
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.

Oncology Co. Receives Buy Rating for New Drug Trials

Research Report
  ()
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report.

Trial Results of New Pneumococcal Vaccine Compelling

Research Report
  ()
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report.

Biotech Rated Outperform Advances Top Drug Candidate

Research Report
  ()
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report.

Phase 3 Trial in Progress of New Ichthyosis Treatment

Research Report
  ()
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report.

Phase 2b Trial of New Drug for Ovarian Cancer Starts

Research Report
  ()
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.

Safety Data From One Trial of New Drug Helpful to Another

Research Report
  ()
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report.

Target Price on Texas-Based Drug Co. Implies 1,929% ROI

Research Report
  ()
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report.

New Treatment for Ovarian Cancer Shows Promise

Research Report
  ()
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report.

Coverage Launched on Drug Co. With 140% Upside

Research Report
  ()
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.

Trial of New Ophthalmic Drug Now Enrolled

Research Report
  ()
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report.

FDA Approval of New Gout Drug Likely, Analyst Says

Research Report
  ()
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report.

Coverage Launched on Canadian Specialty Pharma Co.

Research Report
  ()
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.

New Skin Gene Therapy Gets PDUFA Date

Research Report
  ()
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.

New Drug for Hearing Loss Approved for Clinical Trials

Research Report
  ()
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.

Biopharma Gains Another Shot on Goal With IND Approval

Research Report
  ()
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report
  ()
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report
  ()
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.

Target Price Boosted 400% on Biopharma Co.

Research Report
  ()
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Showing Results: 1 to 20 of 20